Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Baxter Announces Long-Term Partnership in Brazil

Published: Friday, November 09, 2012
Last Updated: Friday, November 09, 2012
Bookmark and Share
Company to expand access to recombinant FVIII hemophilia treatment.

Baxter International Inc. has announced an exclusive 20-year partnership with Hemobrás (Empresa Brasileira de Hemoderivados e Biotechnologia) to provide hemophilia patients in Brazil greater access to recombinant factor VIII (rFVIII) therapy for the treatment of hemophilia A.

Hemophilia A is a genetic condition in which the body does not produce enough clotting protein factor VIII.

It is estimated that more than 10,000 people in Brazil are living with hemophilia A, and the vast majority are treated with plasma-derived FVIII therapy.

Baxter recently highlighted the importance of developing innovative business models, including public and private partnerships, aimed at improving the quality of and access to care in both developed and emerging markets.

"Our unique collaboration with Hemobrás is a demonstration of Baxter's leadership in hemophilia, reflects our expertise and commitment to the community, and positions us as an attractive partner that can make a significant impact on expanding access to quality care to patients around the world," said Robert L. Parkinson, Jr., Baxter chairman and chief executive officer.

Parkinson continued, "This agreement establishes Baxter as the provider of choice in Brazil and builds upon Baxter's long-standing presence in this large and growing market."

Through this innovative partnership, Baxter will be the exclusive provider of Brazil's recombinant FVIII treatment over the next 10 years while the companies work together on the technology transfer to support development of local manufacturing capacity by Hemobrás.

Baxter will receive cash payments for product it supplies to Hemobrás and, following completion of the technology transfer, royalties on recombinant FVIII produced by Hemobrás. The company expects peak annual sales to exceed $200 million.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Baxter to Acquire Oncaspar® Portfolio for Leukemia
New portfolio strengthens leadership in rare and orphan diseases for Baxter, expected to become Baxalta by mid-2015.
Saturday, May 16, 2015
Baxter to Divest Vero Cell Vaccines Platform to Nanotherapeutics
Agreement includes all assets related to the platform, including vaccines for H5N1, H1N1 and seasonal influenza.
Thursday, December 18, 2014
Baxter to Form New Global Innovation and R&D Center
Company plans to form new center near Boston for its biopharmaceuticals business.
Friday, October 10, 2014
Baxter and Merrimack Enter into Exclusive Ex-U.S. Licensing Agreement
Baxter gains exclusive commercialization rights for all potential indications of MM-398 in all other geographies outside Taiwan.
Friday, September 26, 2014
Baxter Acquires AesRx, LLC
Program carries potential to address significant unmet patient need.
Thursday, July 10, 2014
Baxter Announces Topline Results of Phase III Study of Immunoglobulin for Alzheimer's
Phase III clinical study of immunoglobulin (IG) did not meet its co-primary endpoints of reducing cognitive decline and preserving functional abilities in patients with mild to moderate Alzheimer’s disease.
Thursday, May 09, 2013
Baxter Announces FDA Approval of ADVATE 4000 IU Dosage Strength
New size expands convenience options for hemophilia A patients.
Wednesday, July 18, 2012
Baxter Announces Biologics Capacity Expansion
Plan includes new manufacturing site in Georgia and creation of more than 2,000 U.S. jobs.
Friday, April 20, 2012
Scientific News
The Genetic Roots of Adolescent Scoliosis
Scientists at the RIKEN Center for Integrative Medical Sciences in collaboration with Keio University in Japan have discovered a gene that is linked to susceptibility of Scoliosis.
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
Understanding the Molecular Origin of Epigenetic Markers
Researchers at IRB Barcelona discover the molecular mechanism that determines how epigenetic markers influence gene expression.
HIV Susceptibility Linked to Little-Understood Immune Cell Class
High levels of diversity among immune cells called natural killer cells may strongly predispose people to infection by HIV, and may be driven by prior viral exposures, according to a new study.
Diagnostic Test Developed for Enterovirus D68
researchers at Washington University School of Medicine in St. Louis have developed a diagnostic test to quickly detect enterovirus D68 (EV-D68), a respiratory virus that caused unusually severe illness in children last year.
How a Kernel Got Naked and Corn Became King
Ten thousand years ago, a golden grain got naked, brought people together and grew to become one of the top agricultural commodities on the planet.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
New Material Opens Possibilities for Super-Long-Acting Pills
A pH-responsive polymer gel could create swallow able devices, including capsules for ultra-long drug delivery.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!